Madrigal Pharmaceuticals Nears EU Approval for REZDIFFRA, Expanding Hope for MASH Patients – Patient Worthy

Madrigal Pharmaceuticals Nears EU Approval for REZDIFFRA, Expanding Hope for MASH Patients – Patient Worthy

Madrigal Pharmaceuticals is making significant strides in its mission to address metabolic dysfunction-associated steatohepatitis (MASH), as the company’s lead drug, REZDIFFRA, edges closer to regulatory approval in the European Union. Already the first and only FDA-approved treatment for MASH (formerly known as NASH) in the United States, REZDIFFRA’s potential entry into the European market marks […]